文献速递垂体与肾上腺疾病

墨西哥肢端肥大症登记研究:诊断时临床与生化特征及治疗结局

The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes.
PubMed 文献 · J Clin Endocrinol Metab · 2016-07-18

高血压、糖耐量异常、糖尿病和血脂异常分别占27%、18.4%、30%和24%。经蝶手术是72%患者的首选治疗,药物治疗主要和辅助使用分别占26%和54%。

要点

  • 诊断时IGF-1水平及合并高血压与糖尿病发生显著相关。
  • 经蝶手术为72%患者的主要治疗,药物治疗主要和辅助使用分别占26%和54%。

核心结论

  • MAR是同类疾病中规模最大且首个非欧洲的登记研究。
  • 研究结果强调因资源可及性差异导致的国内治疗选择差异。

研究设计与样本

  • MAR于2009年创建,采用专门设计的在线平台收集来自三个机构共24个参与中心的数据。
  • 仅纳入1990年后诊断的患者,共登记2057例(女性51%,诊断时平均年龄41.1±24.5岁)。

主要发现

  • 高血压、糖耐量异常、糖尿病和血脂异常分别占27%、18.4%、30%和24%。
  • 诊断时IGF-1水平及合并高血压与糖尿病发生显著相关。
  • 经蝶手术为72%患者的主要治疗。
  • 药物治疗(主要为生长抑素类似物)主要和辅助使用分别占26%和54%;治疗选择在三个参与机构间存在差异,两个以药物治疗为主,第三个以放疗为主;治疗结局与欧洲登记研究报告相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Acromegaly is a systemic disorder caused by a GH-secreting pituitary adenoma. As with other rare diseases, acromegaly registries developed in various European countries have provided us with important information. OBJECTIVE: The objective of the study was to analyze the epidemiological, clinical, biochemical, and therapeutic data from the Mexican Acromegaly Registry (MAR). SETTING: The setting of the study was a nationwide patient registry. DESIGN AND METHODOLOGY: The MAR was created in 2009. It gathers data from 24 participating centers belonging to three different institutions using a specifically designed on-line platform. Only patients diagnosed after 1990 were included in the program. RESULTS: A total of 2057 patients (51% female, mean age at diagnosis 41.1 ± 24.5 y) have been registered for an estimated prevalence of 18 cases per 1 million inhabitants. Hypertension, glucose intolerance, diabetes, and dyslipidemia were present in 27%, 18.4%, 30%, and 24% of the patients, respectively. The IGF-1 level at diagnosis and the concomitant presence of hypertension were significantly associated with the development of diabetes. Transsphenoidal surgery was the primary treatment in 72% of the patients. Pharmacological treatment, mostly with somatostatin analogs, was administered primarily and adjunctively in 26% and 54% of the patients, respectively. Treatment choice varied among the three participating institutions, with the predominance of pharmacological therapy in two of them and of radiation therapy in the third. Therapeutic outcomes were similar to those reported in the European registries. CONCLUSIONS: The MAR is the largest and first non-European registry of the disease. Our findings highlight important within-country differences in treatment choice due to variations in the availability of resources.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. J Clin Endocrinol Metab. 2016. PMID: 27428551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。